China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine
⬇ $AIM Vaccine(06660)$ - Weight loss and Alzheimer's disease (AD) would generate different investment returns.We're conservative about the outlook of GLP-1 gene therapy.We consider AIM Vaccine risky and recommend staying away
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-oct-20-investment-returns-on-weight-loss-ad-glp-1-gene-therapy-aim-vaccine?utm_source=tiger_community
By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community
On AIM Vaccine (06660):- https://www.smartkarma.com/entities/aim-vaccine-co-ltd?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
